BS_NYS8TRCB
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 80.35479632063074
- age_years
- 11.011
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.490
- INFLAMMATORY_RESPONSE+0.465
- INTERFERON_ALPHA_RESPONSE+0.399
- ALLOGRAFT_REJECTION+0.392
- COMPLEMENT+0.370
- KRAS_SIGNALING_DN+0.369
- PANCREAS_BETA_CELLS+0.348
- INTERFERON_GAMMA_RESPONSE+0.347
- MYOGENESIS+0.343
- TNFA_SIGNALING_VIA_NFKB+0.317
Top 10 suppressed
- E2F_TARGETS-0.629
- MYC_TARGETS_V1-0.617
- MYC_TARGETS_V2-0.570
- G2M_CHECKPOINT-0.560
- DNA_REPAIR-0.489
- UNFOLDED_PROTEIN_RESPONSE-0.457
- PROTEIN_SECRETION-0.374
- OXIDATIVE_PHOSPHORYLATION-0.362
- MTORC1_SIGNALING-0.315
- GLYCOLYSIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0WVJYM9R | pilocytic astrocytoma | — | 0.949 |
| 2 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.930 |
| 3 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.917 |
| 4 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.916 |
| 5 | MDT-AP-2888 | Med | Medulloblastoma | 0.907 |
| 6 | BS_BA6AZWB3 | Med | Medulloblastoma | 0.898 |
| 7 | BS_YB2RXRHT | pilocytic astrocytoma | — | 0.897 |
| 8 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.895 |
| 9 | a802b49c.736d.427c.bcca.8375c4171284 | — | cohortA1 | 0.893 |
| 10 | SRR1397008 | GTEX | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.490 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.465 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.399 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.392 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.369 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.348 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.347 | Idelalisib | — uncovered |
| MYOGENESIS | 0.343 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.317 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.269 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.248 | Temsirolimus | — uncovered |
| COAGULATION | 0.223 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.222 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.221 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.205 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.194 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.181 | Inavolisib | — uncovered |